| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.006 |
0.9 |
| mRNA |
CAL-101 |
CTRPv2 |
pan-cancer |
AAC |
0.0063 |
0.9 |
| mRNA |
tosedostat |
CTRPv2 |
pan-cancer |
AAC |
-0.0062 |
0.9 |
| mRNA |
AC55649 |
CTRPv2 |
pan-cancer |
AAC |
-0.0062 |
0.9 |
| mRNA |
UNC0638 |
GDSC1000 |
pan-cancer |
AAC |
0.0047 |
0.9 |
| mRNA |
WZ8040 |
CTRPv2 |
pan-cancer |
AAC |
0.0061 |
0.9 |
| mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0051 |
0.9 |
| mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0079 |
0.9 |
| mRNA |
AUY922 |
GDSC1000 |
pan-cancer |
AAC |
-0.0052 |
0.9 |
| mRNA |
Carboplatin |
CTRPv2 |
pan-cancer |
AAC |
-0.0052 |
0.9 |